Evidence map›Paper›PMID 39655591›Full record

ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2024

Prevalence of SARS-COV-2 infection and outcomes in Greek sarcoidosis patients.

Ourania Kotsiou, Paraskevi Kirgou, Argyrios Tzouvelekis, Lykourgos Kolilekas, Effrosyni Manali, Spyros Papiris, Despina Papakosta, Katerina Antoniou, Ilias Papanikolaou, Paschalis Steiropoulos and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Ourania KotsiouLaboratory of Human Pathophysiology, Department of Nursing, School of Health Sciences, University of Thessaly, Larissa, Greece.
Paraskevi KirgouDepartment of Respiratory Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
Argyrios TzouvelekisDepartment of Respiratory and Internal Medicine, Faculty of Medicine, University of Patras, Patras, Greece.
Lykourgos Kolilekas7th Pulmonary Department, Athens Chest Hospital "Sotiria", Athens, Greece.
Effrosyni Manali2nd Pulmonary Medicine Department, General University Hospital "Attikon", Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Spyros Papiris2nd Pulmonary Medicine Department, General University Hospital "Attikon", Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Despina PapakostaPulmonary Department, Aristotle University of Thessaloniki, "G. Papanikolaou" Hospital, Exochi, Thessaloniki, Greece.
Katerina AntoniouDepartment of Thoracic Medicine, Heraklion University Hospital, Medical School, University of Crete, Heraklion, Greece.
Ilias PapanikolaouPulmonary Department, Corfu General Hospital, Corfu, Greece.
Paschalis SteiropoulosDepartment of Pneumonology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Ioannis Tomos5th Pulmonary Medicine Department, "Sotiria" Chest Diseases Hospital of Athens, Athens, Greece.
Theodoros KarampitsakosDepartment of Respiratory and Internal Medicine, Faculty of Medicine, University of Patras, Patras, Greece.
Anastasia Levounets7th Pulmonary Department, Athens Chest Hospital "Sotiria", Athens, Greece.
Evagelia FoukaPulmonary Department, Aristotle University of Thessaloniki, "G. Papanikolaou" Hospital, Exochi, Thessaloniki, Greece.
Georgios SpyropoulosPulmonary Department, Aristotle University of Thessaloniki, "G. Papanikolaou" Hospital, Exochi, Thessaloniki, Greece.
Semeli MastrodimouDepartment of Thoracic Medicine, Heraklion University Hospital, Medical School, University of Crete, Heraklion, Greece.
Ourania PapaioannouDepartment of Respiratory and Internal Medicine, Faculty of Medicine, University of Patras, Patras, Greece.
Maria Kallieri2nd Pulmonary Medicine Department, General University Hospital "Attikon", Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Nikoleta KosmidouPulmonary Department, Aristotle University of Thessaloniki, "G. Papanikolaou" Hospital, Exochi, Thessaloniki, Greece.
Nikoleta BizymiDepartment of Thoracic Medicine, Heraklion University Hospital, Medical School, University of Crete, Heraklion, Greece.
Nikolaos ZikosDepartment of Respiratory Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
Ilias DimeasDepartment of Respiratory Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
Foteini MalliRespiratory Disorders Laboratory, Department of Nursing, School of Health Sciences, University of Thessaly, Larissa, Greece.
Zoe DaniilDepartment of Respiratory Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimThere is limited data on the prevalence of SARS-COV-2 in sarcoidosis patients and the underlying parameters linked to severity. We aimed to conduct a national multicenter study to explore the prevalence of SARS-COV-2 in sarcoidosis patients and investigate its impact on hospitalization and infection rates, describe the characteristics of the infected population and assess the role of these characteristics in determining the likelihood of infection or hospitalization.

methodsWe recruited all the adult sarcoidosis patients with who were examined across eight Greek Health Interstitial Lung Disease Referral Centers from the beginning of the pandemic until August 1, 2022. All the data was collected using structured questionnaires.

results530 sarcoidosis patients with a mean age of 54±12 years, 60% of whom were females, were recruited. 43% of them were under corticosteroid treatment, and 39% were under additional immunosuppression. 18% of Greek sarcoidosis patients were infected by the virus, which is a lower rate than the general population. The infection was mainly mild. Only one-fifth of the infected sarcoidosis patients required hospitalization, and no deaths or ICU admissions were recorded. Vaccination was found to be associated with a reduced likelihood of infection. Younger age, a longer period since diagnosis, abnormal PET-CT findings, and immunosuppression were associated with an increased probability of infection.

conclusionsThe COVID-19 infection rate among Greek sarcoidosis patients was lower than the general population. Fewer than 20% needed hospitalization. There were no deaths or ICU admissions. Vaccination reduces the likelihood of infection. Younger age, longer diagnosis, abnormal PET-CT findings, and immunosuppression increased the chance of infection.

Identifiers

PMID39655591
PMCPMC11708959

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.